Cover Image
市場調查報告書

非洲昏睡病(African trypanosomiasis非洲錐蟲病):開發中產品分析

African Trypanosomiasis - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 265423
出版日期 內容資訊 英文 49 Pages
訂單完成後即時交付
價格
Back to Top
非洲昏睡病(African trypanosomiasis非洲錐蟲病):開發中產品分析 African Trypanosomiasis - Pipeline Review, H2 2016
出版日期: 2016年08月31日 內容資訊: 英文 49 Pages
簡介

非洲昏睡病又名非洲錐蟲病,是由於寄生蟲布氏椎蟲寄生而感染,透過舌蠅的刺咬傳播給人類。症狀有不安感、整天嗜睡、發燒、頭痛、失眠、心情變化、嗜睡(無法控制的情況)、盜汗、身體淋巴節腫脹、虰咬部分腫起、皮膚發紅、會疼痛的結痂化、肌肉無力等,治療方法有使用抗原蟲藥等。

本報告網羅全球非洲昏睡症治療藥的開發平台資訊,提供您目前開發平台狀況和最新趨勢,藥物簡介,主要企業及開發中的產品檢討等資訊,為您概述為以下內容。

目錄

簡介

  • 分析範圍

非洲昏睡病概要

治療藥的開發

  • 非洲昏睡病轉動開發中產品:概要
  • 非洲昏睡病轉動開發中產品:比較分析

非洲昏睡病:開發中的治療藥:各企業

非洲昏睡病:開發中的治療藥:各大學·研究機關

非洲昏睡病:開發中產品概況

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

非洲昏睡病:開發中的產品:各企業

非洲昏睡病:開發中的產品:各大學·研究機關

非洲昏睡病:治療藥的開發企業

  • Anacor Pharmaceuticals, Inc.
  • Sanofi
  • Scynexis, Inc

非洲昏睡病:治療藥的評估

  • 單劑治療藥
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

最新的開發平台趨勢

暫停中的計劃

中止開發的產品

產品開發里程碑

  • 關注的新聞·新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8417IDB

Summary

Global Markets Direct's, 'African Trypanosomiasis - Pipeline Review, H2 2016', provides an overview of the African Trypanosomiasis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for African Trypanosomiasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for African Trypanosomiasis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of African Trypanosomiasis
  • The report reviews pipeline therapeutics for African Trypanosomiasis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved African Trypanosomiasis therapeutics and enlists all their major and minor projects
  • The report assesses African Trypanosomiasis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for African Trypanosomiasis

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for African Trypanosomiasis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding African Trypanosomiasis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • African Trypanosomiasis Overview
  • Therapeutics Development
    • Pipeline Products for African Trypanosomiasis - Overview
    • Pipeline Products for African Trypanosomiasis - Comparative Analysis
  • African Trypanosomiasis - Therapeutics under Development by Companies
  • African Trypanosomiasis - Therapeutics under Investigation by Universities/Institutes
  • African Trypanosomiasis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • African Trypanosomiasis - Products under Development by Companies
  • African Trypanosomiasis - Products under Investigation by Universities/Institutes
  • African Trypanosomiasis - Companies Involved in Therapeutics Development
    • Novartis AG
    • Sanofi
    • Scynexis, Inc.
  • African Trypanosomiasis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AN-5568 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DDD-100097 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • fexinidazole - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GNF-6702 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • melarsoprol hydroxypropylbetadex - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Peptides for Sleeping Sickness - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for African Trypanosomiasis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for African Trypanosomiasis and Infectious Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Infectious Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Protozoal Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Sleeping Sickness - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Leucyl-tRNA Synthetase (LeuRS) for Human African Trypanosomiasis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit N-Myristoyltransferase for African Trypanosomiasis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • African Trypanosomiasis - Dormant Projects
  • African Trypanosomiasis - Discontinued Products
  • African Trypanosomiasis - Product Development Milestones
    • Featured News & Press Releases
      • Sep 08, 2015: Clinical trial for first oral drug candidate specifically developed for sleeping sickness
      • Mar 12, 2012: Anacor Announces Commencement Of Phase I Clinical Trials Of Boron-Based Compound For Sleeping Sickness
      • Jun 28, 2011: Anacor Pharmaceuticals Partnership Advances New Drug Candidate To Combat Sleeping Sickness
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for African Trypanosomiasis, H2 2016
  • Number of Products under Development for African Trypanosomiasis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • African Trypanosomiasis - Pipeline by Novartis AG, H2 2016
  • African Trypanosomiasis - Pipeline by Sanofi, H2 2016
  • African Trypanosomiasis - Pipeline by Scynexis, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • African Trypanosomiasis - Dormant Projects, H2 2016
  • African Trypanosomiasis - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for African Trypanosomiasis, H2 2016
  • Number of Products under Development for African Trypanosomiasis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top